Mergers & acquisitions
Pfizer acquired China/Asia rights for Cresemba, an antifungal drug developed by Swiss pharma Basilea, in a $226M deal.
Esaote S.p.A., an Italian medical imaging company, has been acquired by a group of China investors.
Medtronic confirmed that it bought Crospon but declined to disclose the value of the deal.
GlaxoSmithKline will scout for deal opportunities in cancer medicine, as well as immunology, as the drugmaker seeks to rebuild its presence in oncology, its new head of pharmaceuticals told Reuters.
Despite a purge of the leadership team at Alexion, a key investor believes the company needs to do more in order to address its damaged reputation and lift its stock price.
Sucampo has received takeover interest, although there are no hints about who has shown an interest.
Gilead will pay an upfront payment of $175M, with additional milestone payments of up to $322M.
Entellus’ ENT portfolio is led by e XprESS Multi-Sinus Dilation System and the LATERA Absorbable Nasal Implant.
Pfizer is no stranger to taking the big gambles-note the company’s attempts to buy Astra in 2014 and Allergan in 2016.
The revised offer of $49.25 per share represents an increase of 17.3 percent to the previously announced $42 per share, the company said.
PRESS RELEASES